Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26220%2F10%3APU89748" target="_blank" >RIV/00216305:26220/10:PU89748 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

čeština

Název v původním jazyce

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Popis výsledku v původním jazyce

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis isstill limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed asa promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Název v anglickém jazyce

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Popis výsledku anglicky

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis isstill limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed asa promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Druh

O - Ostatní výsledky

CEP obor

FS - Lékařská zařízení, přístroje a vybavení

OECD FORD obor

—

Projekt

<a href="/cs/project/GA102%2F09%2F1690" target="_blank" >GA102/09/1690: Zvýšení potenciálu kontrastních zobrazovacích technik magnetické rezonance a ultrasonografie v lékařské diagnostice</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů